Peroxisomal proliferation induced by treatment with clofibrate in a patient with a peroxisomal disease.
The induction of peroxisomal proliferation in liver parenchymal cells of rats fed a diet containing clofibrate, a hypolipidemic drug, is a well-established event. However, the available data on human hepatocytes in vivo and in vitro indicate that agents that induce peroxisomal proliferation in rats and mice have no effect on human liver cells. The authors are reporting the case of a patient with clinical and laboratory diagnosis of X-linked-adrenoleukodystrophy. In an initial liver biopsy, a reduced volume fraction of peroxisomes was found (Vv. = .012) after a morphometric analysis, initiating treatment with clofibrate at a dose of 1.5 g/d. The administration of clofibrate was maintained for 7 yr. Liver biopsies were taken after 2, 4, and 7 yr, to follow the peroxisomal response. Results demonstrated a 500% increase in peroxisomal Vv. (.060) after 2 yr of treatment, compared with the pretreatment Vv. In subsequent biopsies, the peroxisomal Vv. value was maintained at 225 and 183% increases above the pretreatment biopsy (.027 and .022, respectively).
Sepúlveda
J
J
Departamento de Histología, Facultad de Medicina de la U.A.N.L., Monterrey, N.L. JSEPULVE@CCR.DSI.UANL.MX
Gutiérrez
F
F
Moreno
M
M
Hernández
A
A
D000293:Adolescent; D000328:Adult; D000818:Animals; D002994:Clofibrate / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D018901:Peroxisomal Disorders / Q000188:drug therapy* / Q000473:pathology*; D020675:Peroxisomes / Q000187:drug effects / Q000473:pathology*
D000960:Hypolipidemic Agents; D002994:Clofibrate